Brian Van Tine, MD, PhD, on Bringing Cell Therapy Into Synovial Sarcoma Treatment

Video

The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel.

“We work with AdaptImmune on the SPEAR T-cell, which is a modified T cell, where we look at patients that are HLA-A*0-positive and express MAGEA4. This was a trial that I've been working on since almost the very beginning of the phase 1 that was presented in 2017 at ESMO, and there's been multiple updates of the registrational phase 2which has enabled the therapy to be up for a biologics license application. At Tandem, I’m giving a talk to bone marrow transplantation doctors.”

Afamitresgene autoleucel (afami-cel; Adaptimmune Therapeutics) has continued to demonstrate continued clinical responses in patients with late-stage synovial sarcoma in the phase 2 SPEARHEAD-1 study (NCT04044768). Investigator Brian Van Tine, MD, PhD, professor medicine and pediatrics at Washington University in St. Louis, gave a talk on afami-cel, how its builds on the data seen so far in the field, and protocol changes to support implementation of cell therapy in sarcoma at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke with Van Tine to learn more about afami-cel and how it could potentially improve outcomes for patients with synovial sarcoma, a disease area that has previously not seen many novel therapies. He overviewed the data generated and how it has favorably matured.

For more coverage of the 2023 Tandem Meetings, click here.

REFERENCE
Van Tine B. Adoptive cell therapy for sarcoma. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida.
Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.